

## 8 Literaturverzeichnis

1. Carretero OA, Oparil S. Essential hypertension. Part I: definition and etiology. *Circulation*. 2000;101:329-35.
2. Gasse C, Hense HW, Stieber J, Doring A, Liese AD, Keil U. Assessing hypertension management in the community: trends of prevalence, detection, treatment, and control of hypertension in the MONICA Project, Augsburg 1984-1995. *J Hum Hypertens*. 2001;15:27-36.
3. Mensah GA, Croft JB, Giles WH. The heart, kidney, and brain as target organs in hypertension. *Cardiol Clin*. 2002;20:225-47.
4. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. *J Hypertens*. 1999;17:151-83.
5. Wofford MR, King DS, Wyatt SB, Jones DW. Secondary Hypertension: Detection and Management for the Primary Care Provider. *J Clin Hypertens*. 2000;2:124-131.
6. Witzleb E. Funktionen des Gefäßsystems. In: Schmidt FR, Thews G, eds. *Physiologie des Menschen*. 24. ed. Berlin: Springer-Verlag; 1990:505-572.
7. Bassenge E, Busse R. Endothelabhängige Störungen der Durchblutungsregulation. In: Hierholzer K, Schmidt RF, eds. *Pathophysiologie des Menschen*. Weinheim: VCH; 1991.
8. Lüscher TF, Boulanger CM, Dohi Y, Yang ZH. Endothelium-derived contracting factors. *Hypertension*. 1992;19:117-30.
9. Stumpe KO. Blutdruck. In: Krück M, ed. *Pathophysiologie*. München, Wien, Baltimore: Urban & Schwarzenberg; 1994:122-145.
10. Fouad FM. Cardiac function and dysfunction in hypertension. *Clin J Med*. 1994;61:351-355.
11. Emmett JD. A review of heart rate and blood pressure responses in the cold in healthy subjects and coronary artery disease patients. *J Cardiopulm Rehabil*. 1995;15:19-24.
12. Folkow B. Physiological aspects of primary hypertension. *Physiol Rev*. 1982;62:347-504.
13. Robbins. *Pathologic basis of disease*. Philadelphia, USA: W. B. Saunders; 1999.
14. Hypertension WHO/ISH. 1999 WHO/ISH hypertension guidelines. 1999 WHO/ISH hypertension guidelines. 1999.
15. Blood pressure, cholesterol, and stroke in eastern Asia. Eastern Stroke and Coronary Heart Disease Collaborative Research Group. *Lancet*. 1998;352:1801-7.

16. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet*. 1990;335:765-74.
17. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham study. *N Engl J Med*. 1972;287:781-7.
18. Chambless LE, Folsom AR, Davis V, Sharrett R, Heiss G, Sorlie P, Szklo M, Howard G, Evans GW. Risk factors for progression of common carotid atherosclerosis: the Atherosclerosis Risk in Communities Study, 1987-1998. *Am J Epidemiol*. 2002;155:38-47.
19. Oren A, Vos LE, Uiterwaal CS, Grobbee DE, Bots ML. Cardiovascular risk factors and increased carotid intima-media thickness in healthy young adults: the Atherosclerosis Risk in Young Adults (ARYA) Study. *Arch Intern Med*. 2003;163:1787-92.
20. Doerr W. [Arteriosclerosis: morbid anatomy (author's transl)]. *Langenbecks Arch Chir*. 1975;339:137-51.
21. Doerr W. The pathogenesis of cardiac infarction. A few comments on some unanswered questions. *Virchows Arch A Pathol Pathol Anat*. 1977;373:177-90.
22. Dahl LK, Knudsen KD, Iwai J. Humoral transmission of hypertension: evidence from parabiosis. *Circ Res*. 1969;24:Suppl:21-33.
23. Bianchi G, Fox U, Di Francesco GF, Giovanetti AM, Pagetti D. Blood pressure changes produced by kidney cross-transplantation between spontaneously hypertensive rats and normotensive rats. *Clin Sci Mol Med*. 1974;47:435-48.
24. Curtis JJ, Luke RG, Dustan HP, Kashgarian M, Whelchel JD, Jones P, Diethelm AG. Remission of essential hypertension after renal transplantation. *N Engl J Med*. 1983;309:1009-15.
25. de Wardener HE, MacGregor GA. The natriuretic hormone and essential hypertension. *Lancet*. 1982;1:1450-4.
26. de Wardener HE, Clarkson EM. Concept of natriuretic hormone. *Physiol Rev*. 1985;65:658-759.
27. Blaustein MP, Hamlyn JM. Sodium transport inhibition, cell calcium, and hypertension. The natriuretic hormone/Na<sup>+</sup>-Ca<sup>2+</sup> exchange/hypertension hypothesis. *Am J Med*. 1984;77:45-59.

28. de The H, Devynck MA, Rosenfeld J, Pernollet MG, Elghozi JL, Meyer P. Plasma sodium pump inhibitor in essential hypertension and normotensive subjects with hypertensive heredity. *J Cardiovasc Pharmacol.* 1984;6:S49-54.
29. Zidek W, Heckmann U, Lange-Asschenfeldt H, Losse H, Vetter H. Humoral factors in the pathogenesis of primary hypertension. *Klin Wochenschr.* 1985;63:94-6.
30. Zidek W, Heckmann U, Losse H, Vetter H. Effects on blood pressure of cross circulation between spontaneously hypertensive and normotensive rats. *Clin Exp Hypertens.* 1986;8:347-54.
31. Schlüter H, Kluth B, Borjesson-Stoll R, Nordhoff E, Zidek W. Partial purification and characterization of a circulating hypertensive factor in spontaneously hypertensive rats. *Eur J Biochem.* 1993;218:67-73.
32. Zidek W, Sachinidis A, Spieker C, Storkebaum W. Effect of plasma from hypertensive subjects on  $Ca^{2+}$ -transport in permeabilized human neutrophils. *Clin Sci.* 1988;74:53-6.
33. Zidek W, Bachmann J, Schlüter H, Witzel H, Storkebaum W, Sachinidis A. Effect of plasma from essential hypertensives on tension of aortic strips. *Clin Exp Hypertens.* 1990;12:365-81.
34. Bachmann J, Schlüter H, Storkebaum W, Witzel H, Wessels F, Zidek W. Effect of plasma from patients with essential hypertension on vascular resistance in the isolated perfused rat kidney. *Clin Sci* 1991;80:17-23.
35. Bachmann J, Schlüter H, Storkebaum W, Witzel H, Zidek W. Effect of plasma from essential hypertensives on vascular tone of aortic strips, isolated perfused mesentery and isolated perfused kidney. *Life Sci.* 1990;47:1365-74.
36. Agha A, Schlüter H, König S, Biel K, Tepel M, Zidek W. A novel platelet-derived renal vasoconstrictor agent in normotensives and essential hypertensives. *J Vasc Res.* 1992;29:281-9.
37. Schlüter H, Offers E, Brüggemann G, van der Giet M, Tepel M, Nordhoff E, Karas M, Spieker C, Witzel H, Zidek W. Diadenosine phosphates and the physiological control of blood pressure. *Nature.* 1994;367:186-8.
38. Schlüter H, Gross I, Bachmann J, Kaufmann R, van der Giet M, Tepel M, Nofer JR, Assmann G, Karas M, Jankowski J, Zidek W. Adenosine(5') oligophospho-(5') guanosines and guanosine(5') oligophospho-(5') guanosines in human platelets. *J Clin Invest.* 1998;101:682-8.
39. Luo J, Jankowski J, Knobloch M, Van Der Giet M, Gardanis K, Russ T, Vahlensieck U, Neumann J, Schmitz W, Tepel M, Deng MC, Zidek W, Schlüter H. Identification and

- characterization of diadenosine 5',5'''-P<sub>1</sub>,P<sub>2</sub> - diphosphate and diadenosine 5',5'''-P<sub>1</sub>,P<sub>3</sub>-triphosphate in human myocardial tissue. *Faseb Journal* 1999;13:695-705.
40. Jankowski J, Tepel M, van der Giet M, Tente IM, Henning L, Junker R, Zidek W, Schlüter H. Identification and characterization of Diadenosine-5'- heptaphosphate from human platelets. *J Biol Chem.* 1999;274:23926-31.
  41. Jankowski J, Hagemann J, Tepel M, van Der Giet M, Stephan N, Henning L, Gouni-Berthold I, Sachinidis A, Zidek W, Schlüter H. Dinucleotides as growth-promoting extracellular mediators. Presence of dinucleoside diphosphates Ap<sub>2</sub>A, Ap<sub>2</sub>G, and Gp<sub>2</sub>G in releasable granules of platelets. *J Biol Chem.* 2001;276:8904-9.
  42. Jankowski J, Potthoff W, van der Giet M, Tepel M, Zidek W, Schlüter H. High-performance liquid chromatographic assay of the diadenosine polyphosphates in human platelets. *Anal Biochem.* 1999;269:72-78.
  43. Rodriguez del Castillo A, Torres M, Delicado EG, Miras-Portugal MT. Subcellular distribution studies of diadenosine polyphosphates--Ap<sub>4</sub>A and Ap<sub>5</sub>A--in bovine adrenal medulla: presence in chromaffin granules. *J Neurochem.* 1988;51:1696-703.
  44. Pintor J, Diaz-Rey MA, Torres M, Miras-Portugal MT. Presence of diadenosine polyphosphates--Ap<sub>4</sub>A and Ap<sub>5</sub>A--in rat brain synaptic terminals. Ca<sup>2+</sup> dependent release evoked by 4-aminopyridine and veratridine. *Neurosci Lett.* 1992;136:141-4.
  45. Zimmermann H, Volkandt W, Wittich B, Hausinger A. Synaptic vesicle life cycle and synaptic turnover. *J Physiol Paris.* 1993;87:159-70.
  46. Castillo CJ, Moro MA, Del Valle M, Sillero A, Garcia AG, Sillero MA. Diadenosine tetraphosphate is co-released with ATP and catecholamines from bovine adrenal medulla. *J Neurochem.* 1992;59:723-32.
  47. Pintor J, Torres M, Miras-Portugal MT. Carbachol induced release of diadenosine polyphosphates--Ap<sub>4</sub>A and Ap<sub>5</sub>A-- from perfused bovine adrenal medulla and isolated chromaffin cells. *Life Sci.* 1991;48:2317-24.
  48. Luo J, Jankowski J, Tepel M, von der Giet M, Zidek W, Schlüter H. Identification of diadenosine hexaphosphate in human erythrocytes. *Hypertension.* 1999;34:872-5.
  49. Oberdisse H, Kuschinsky. *Pharmakologie und Toxikologie.* In. Berlin, Heidelberg, New York: Springer; 2002:41-44.
  50. van der Giet M, Khattab M, Borgel J, Schlüter H, Zidek W. Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney. *Br J Pharmacol.* 1997;120:1453-60.

51. Tepel M, Jankowski J, Schlüter H, Bachmann J, van der Giet M, Ruess C, Terliesner J, Zidek W. Diadenosine polyphosphates' action on calcium and vessel contraction. *Am J Hypertens.* 1997;10:1404-10.
52. van der Giet M, Jankowski J, Schlüter H, Zidek W, Tepel M. Mediation of the vasoactive properties of diadenosine tetraphosphate via various purinoceptors. *J Hypertens.* 1998;16:1939-43.
53. Tepel M, Bachmann J, Schlüter H, Zidek W. Diadenosine polyphosphates increase cytosolic calcium and attenuate angiotensin-II-induced changes of calcium in vascular smooth muscle cells. *J Vasc Res.* 1996;33:132-8.
54. Lewis CJ, Gitterman DP, Schlüter H, Evans RJ. Effects of diadenosine polyphosphates (Ap<sub>(n)</sub>As) and adenosine polyphospho guanosines (Ap<sub>(n)</sub>Gs) on rat mesenteric artery P<sub>2X</sub> receptor ion channels. *Br J Pharmacol.* 2000;129:124-30.
55. van der Giet M, Westhoff T, Cinkilic O, Jankowski J, Schlüter H, Zidek W, Tepel M. The critical role of adenosine and guanosine in the affinity of dinucleoside polyphosphates to P<sub>2X</sub>-receptors in the isolated perfused rat kidney. *Br J Pharmacol.* 2001;132:467-74.
56. Mantero F, Boscaro M. Glucocorticoid-dependent hypertension. *J Steroid Biochem Mol Biol.* 1992;43:409-13.
57. Verspohl EJ, Johannwille B, Kaiserling-Buddemeier I, Schlüter H, Hagemann J. Diadenosine polyphosphates in cultured vascular smooth-muscle cells and endothelium cells-their interaction with specific receptors and their degradation. *J Pharm Pharmacol.* 1999;51:1175-81.
58. Brandts B, Brandts A, Wellner-Kienitz MC, Zidek W, Schlüter H, Pott L. Non-receptor-mediated activation of IK<sub>(ATP)</sub> and inhibition of IK<sub>(ACh)</sub> by diadenosine polyphosphates in guinea-pig atrial myocytes. *J Physiol (Lond).* 1998;512:407-20.
59. Heidenreich S, Tepel M, Schlüter H, Harrach B, Zidek W. Regulation of rat mesangial cell growth by diadenosine phosphates. *J Clin Invest.* 1995;95:2862-7.
60. Schulze-Lohoff E, Zanner S, Ogilvie A, Sterzel RB. Vasoactive diadenosine polyphosphates promote growth of cultured renal mesangial cells. *Hypertension.* 1995;26:899-904.
61. Jankowski J, Hagemann J, Tepel M, van der Giet M, Stephan N, Henning L, Gouni-Berthold I, Sachinidis A, Zidek W, Schlüter H. Dinucleotides as growth promoting extracellular mediators: Presence of dinucleoside diphosphates Ap<sub>2</sub>A, Ap<sub>2</sub>G and Gp<sub>2</sub>G in releasable granules of platelets. *J Biol Chem.* 2001;276:8904-9.
62. Schmidt R, Thews G. *Physiologie des Menschen.* Berlin Heidelberg New York: Springer-Verlag; 1995.

63. Oberhauser V, Vonend O, Rump LC. Neuropeptide Y and ATP interact to control renovascular resistance in the rat. *J Am Soc Nephrol.* 1999;10:1179-85.
64. Donoso MV, Steiner M, Huidobro-Toro JP. BIBP 3226, suramin and prazosin identify neuropeptide Y, adenosine 5'-triphosphate and noradrenaline as sympathetic cotransmitters in the rat arterial mesenteric bed. *J Pharmacol Exp Ther.* 1997;282:691-8.
65. Sillero MA, Del Valle M, Zaera E, Michelena P, Garcia AG, Sillero A. Diadenosine 5',5''-P<sub>1</sub>,P<sub>4</sub>-tetrphosphate (Ap<sub>4</sub>A), ATP and catecholamine content in bovine adrenal medulla, chromaffin granules and chromaffin cells. *Biochimie.* 1994;76:404-9.
66. Wheelock GD, Sieber KP, Hagedorn HH. Rapid isolation of a neurohormone from mosquito heads by high-performance liquid chromatography. *J Chromatogr.* 1991;542:508-14.
67. Barnes LD, Robinson AK, Mumford CH, Garrison PN. Assay of diadenosine tetraphosphate hydrolytic enzymes by boronate chromatography. *Anal Biochem.* 1985;144:296-304.
68. Goerlich O, Foeckler R, Holler E. Mechanism of synthesis of adenosine(5')tetraphospho(5')adenosine (Ap<sub>4</sub>A) by aminoacyl-tRNA synthetases. *Eur J Biochem.* 1982;126:135-42.
69. Plateau P, Blanquet S. Zinc-dependent synthesis of various dinucleoside 5',5''-P<sub>1</sub>,P<sub>3</sub>-Tri- or 5',5''-P<sub>1</sub>,P<sub>4</sub>-tetrphosphates by escherichia coli lysyl-tRNA synthetase. *Biochemistry.* 1982;21:5273-9.
70. Brevet A, Chen J, Leveque F, Plateau P, Blanquet S. In vivo synthesis of adenylylated bis(5'-nucleosidyl) tetraphosphates (Ap<sub>4</sub>N) by Escherichia coli aminoacyl-tRNA synthetases. *Proc Natl Acad Sci U S A.* 1989;86:8275-9.
71. Guranowski A, Sillero MA, Sillero A. Firefly luciferase synthesizes P<sub>1</sub>,P<sub>4</sub>-bis(5'-adenosyl)tetraphosphate (Ap<sub>4</sub>A) and other dinucleoside polyphosphates. *FEBS Lett.* 1990;271:215-8.
72. Fontes R, Ortiz B, de Diego A, Sillero A, Gunther Sillero MA. Dehydroluciferyl-AMP is the main intermediate in the luciferin dependent synthesis of Ap<sub>4</sub>A catalyzed by firefly luciferase. *FEBS Lett.* 1998;438:190-4.
73. Winkler H, Westhead E. The molecular organization of adrenal chromaffin granules. *Neuroscience.* 1980;5:1803-23.
74. Ornberg RL, Kuijpers GA, Leapman RD. Electron probe microanalysis of the subcellular compartments of bovine adrenal chromaffin cells. Comparison of chromaffin granules in situ and in vitro. *J Biol Chem.* 1988;263:1488-93.

75. Sigel H, Corfu NA. Facilitated formation of high-molecular-weight associates of adenosine 5'-triphosphate (ATP). *Naturwissenschaften*. 1995;82:237-8.
76. McLennan AG. *Ap<sub>4</sub>A and other dinucleoside polyphosphates*. Boca Raton, Florida: CRC Press, Inc.; 1992.
77. Schlüter H, Tepel M, Zidek W. Vascular actions of diadenosine phosphates. *J Auton Pharmacol*. 1996;16:357-62.
78. Jankowski J, Jankowski V, Laufer U, Van Der Giet M, Henning L, Tepel M, Zidek W, Schlüter H. Identification and Quantification of Diadenosine Polyphosphate Concentrations in Human Plasma. *Arterioscler Thromb Vasc Biol*. 2003;23:1231-1238.
79. Jankowski J, Jankowski V, Seibt B, Henning L, Zidek W, Schlüter H. Identification of dinucleoside polyphosphates in adrenal glands. *Biochem Biophys Res Commun*. 2003;304:365-70.
80. Pintor J, Rotllan P, Torres M, Miras-Portugal MT. Characterization and quantification of diadenosine hexaphosphate in chromaffin cells: granular storage and secretagogue-induced release. *Anal Biochem*. 1992;200:296-300.
81. Verspohl EJ, Johannwille B. Diadenosine polyphosphates in insulin-secreting cells: interaction with specific receptors and degradation. *Diabetes*. 1998;47:1727-34.
82. Ripoll C, Martin F, Manuel Rovira J, Pintor J, Miras-Portugal MT, Soria B. Diadenosine polyphosphates. A novel class of glucose-induced intracellular messengers in the pancreatic beta-cell. *Diabetes*. 1996;45:1431-4.
83. Gasmi L, McLennan AG, Edwards SW. Diadenosine polyphosphates induce intracellular Ca<sup>2+</sup> mobilization in human neutrophils via a pertussis toxin sensitive G-protein. *Immunology*. 1997;90:154-9.
84. Miras-Portugal MT, Gualix J, Pintor J. The neurotransmitter role of diadenosine polyphosphates. *FEBS Lett*. 1998;430:78-82.
85. Hohage H, Reinhardt C, Borucki U, Enck G, Schlüter H, Schlatter E, Zidek W. Effects of diadenosine polyphosphates on renal function and blood pressure in anesthetized Wistar rats. *J Am Soc Nephrol*. 1996;7:1216-22.
86. Lüthje J, Baringer J, Ogilvie A. Highly efficient induction of human platelet aggregation in heparinized platelet-rich plasma by diadenosine triphosphate (Ap<sub>3</sub>A). *Thromb Haemost*. 1985;54:469-71.
87. Vartanian A, Prudovsky I, Suzuki H, Dal Pra I, Kisselev L. Opposite effects of cell differentiation and apoptosis on Ap<sub>3</sub>A/Ap<sub>4</sub>A ratio in human cell cultures. *FEBS Lett*. 1997;415:160-2.

88. Ralevic V, Jankowski J, Schlüter H. Structure-activity relationships of diadenosine polyphosphates ( $\text{Ap}_{(n)}\text{As}$ ), adenosine polyphospho guanosines ( $\text{Ap}_{(n)}\text{Gs}$ ) and guanosine polyphospho guanosines ( $\text{Gp}_{(n)}\text{Gs}$ ) at  $\text{P}_2$  receptors in the rat mesenteric arterial bed. *Br J Pharmacol.* 2001;134:1073-83.
89. Castro E, Pintor J, Miras-Portugal MT.  $\text{Ca}^{(2+)}$ -stores mobilization by diadenosine tetraphosphate,  $\text{Ap}_4\text{A}$ , through a putative  $\text{P2Y}$  purinoceptor in adrenal chromaffin cells. *Br J Pharmacol.* 1992;106:833-7.
90. Schlüter H, Zidek W. Application of non-size related separation effects to the purification of biologically active substances with the size-exclusion gel sephacryl 100 high resolution. *J Chromatogr.* 1993;639:17-22.
91. Alvarez-Gonzalez R, Juarez-Salinas H, Jacobson EL, Jacobson MK. Evaluation of immobilized boronates for studies of adenine and pyridine nucleotide metabolism. *Anal Biochem.* 1983;135:69-77.
92. Schlüter H, Jankowski J. Displacement chromatography. Amsterdam: Elsevier; 2000.
93. Regnier FE. Chromatography of complex protein mixtures. *J Chromatogr.* 1987;418:115-43.
94. Kaufmann R, Kirsch D, Spengler B. Sequencing of peptides in a time-of-flight mass spectrometer: evaluation of postsorce decay following matrix-assisted laser desorption ionisation (MALDI). *Int J Mass Spectrom Ion Proc.* 1994;131:355-85.
95. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. *Pharmacol Rev.* 1998;50:413-92.
96. Wildman SS, Brown SG, King BF, Burnstock G. Selectivity of diadenosine polyphosphates for rat  $\text{P2X}$  receptor subunits. *Eur J Pharmacol.* 1999;367:119-23.
97. King BF, Townsend-Nicholson A, Wildman SS, Thomas T, Spyer KM, Burnstock G. Coexpression of rat  $\text{P2X2}$  and  $\text{P2X6}$  subunits in *Xenopus* oocytes. *J Neurosci.* 2000;20:4871-7.
98. Liu M, King BF, Dunn PM, Rong W, Townsend-Nicholson A, Burnstock G. Coexpression of  $\text{P2X(3)}$  and  $\text{P2X(2)}$  receptor subunits in varying amounts generates heterogeneous populations of  $\text{P2X}$  receptors that evoke a spectrum of agonist responses comparable to that seen in sensory neurons. *J Pharmacol Exp Ther.* 2001;296:1043-50.
99. Surprenant A, Schneider DA, Wilson HL, Galligan JJ, North RA. Functional properties of heteromeric  $\text{P2X(1/5)}$  receptors expressed in HEK cells and excitatory junction potentials in guinea-pig submucosal arterioles. *J Auton Nerv Syst.* 2000;81:249-63.



100. Jacobson KA, F. KB, Burnstock G. Pharmacological characterization of P2 (nucleotide) receptors. *Celltransmissions*. 2000;16:3-16.
101. King BF, Burnstock G, Boyer JL, Boeynaems J, Weisman GA, Kennedy C, Jacobson KA, Humphries RG, Abbracchio MP, Gachet C, Miras-Portugal MT. Nucleotide receptors: P2Y receptors. In: Publications. IM, ed. *The IUPHAR compendium of receptor characterization and clas-sification*; 2000.
102. Sen RP, Delicado EG, Castro E, Miras-Portugal MT. Effect of P2Y agonists on adenosine transport in cultured chromaffin cells. *J Neurochem*. 1993;60:613-9.
103. Miras-Portugal MT, Castro E, Mateo J, Pintor J. The diadenosine polyphosphate receptors: P2D purinoceptors. In: Chadwick DJ, Goode JA, eds. *P2 purinoceptors; localization, function and transduction mechanisms*. Chichester, UK; 1996:35-47.
104. Pintor J, Diaz-Rey MA, Miras-Portugal MT. Ap<sub>4</sub>A and ADP-β-S binding to P2 purinoceptors present on rat brain synaptic terminals. *Br J Pharmacol*. 1993;108:1094-9.